Last reviewed · How we verify
Letermovir intravenous
Inhibits human cytomegalovirus (HCMV) replication by targeting the viral terminase complex
Inhibits human cytomegalovirus (HCMV) replication by targeting the viral terminase complex Used for Prevention of cytomegalovirus (CMV) infection in adult recipients of an allogeneic hematopoietic stem cell transplant.
At a glance
| Generic name | Letermovir intravenous |
|---|---|
| Also known as | MK-8228, AIC246, AIC001 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Viral replication inhibitor |
| Target | HCMV terminase complex |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Letermovir is a viral replication inhibitor that specifically targets the HCMV terminase complex, preventing viral DNA maturation and replication.
Approved indications
- Prevention of cytomegalovirus (CMV) infection in adult recipients of an allogeneic hematopoietic stem cell transplant
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Vomiting
Key clinical trials
- Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) (PHASE3)
- Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030) (PHASE2)
- MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) (PHASE3)
- Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
- Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection (PHASE2)
- Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Letermovir intravenous CI brief — competitive landscape report
- Letermovir intravenous updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI